IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0101000
(2005-04-07)
|
등록번호 |
US-8722668
(2014-05-13)
|
발명자
/ 주소 |
|
출원인 / 주소 |
|
인용정보 |
피인용 횟수 :
1 인용 특허 :
74 |
초록
▼
The present invention relates to methods and compositions for treating neuropathic pain and neuropsychiatric disorders by administering agents that are effective in reducing the effective amount, inactivating, and/or inhibiting the activity of a Na+—K+-2Cl− (NKCC) cotransporter. In certain embodimen
The present invention relates to methods and compositions for treating neuropathic pain and neuropsychiatric disorders by administering agents that are effective in reducing the effective amount, inactivating, and/or inhibiting the activity of a Na+—K+-2Cl− (NKCC) cotransporter. In certain embodiments, the Na+—K+-2Cl− co-transporter is NKCC1.
대표청구항
▼
1. A method for treating pain or the perception of pain in a mammalian subject in need thereof comprising administering an effective amount of a composition comprising a Na+K+2Cl− co-transporter antagonist to the subject. 2. The method of claim 1, wherein the Na+K+2Cl− co-transporter antagonist is a
1. A method for treating pain or the perception of pain in a mammalian subject in need thereof comprising administering an effective amount of a composition comprising a Na+K+2Cl− co-transporter antagonist to the subject. 2. The method of claim 1, wherein the Na+K+2Cl− co-transporter antagonist is a NKCC1 co-transporter antagonist. 3. The method of claim 1, wherein the antagonist is a loop diuretic. 4. The method of claim 3, wherein the antagonist is selected from the group consisting of: furosemide; bumetanide; ethacrynic acid; torsemide; azosemide; muzolimine; piretanide; and tripamide. 5. The method of claim 1, wherein the antagonist is selected from the group consisting of thiazide and thiazide-like diuretics. 6. The method of claim 5, wherein the antagonist is selected from the group consisting of bendroflumethiazide; benzthiazide; chlorothiazide; hydrochlorothiazide; hydroflumethiazide; methylclothiazide; polythiazide; trichlormethiazide; chlorthalidone; indapamide; metolazone; and quinethazone. 7. The method of claim 1, wherein the antagonist modulates extracellular ion composition and chloride gradients in nervous system tissue. 8. The method of claim 1, wherein the composition is administered orally, sublingually, nasally, transdermally, intravenously, intracranially, intraperitoneally, subcutaneously, intramuscularly, or by inhalation, spinal tap, direct intrathecal injection, administration into the cerebral spinal fluid via the spinal cord by injection or osmotic pump, or administration in a sustained release formulation. 9. The method of claim 1, wherein the pain is neuropathic pain and said neuropathic pain is selected from the group consisting of diabetic neuropathy; postherpetic neuralgia; cancer-related pain; neurotoxicity-induced pain; spinal cord injury; causalgia or reflex sympathetic dystrophy; trigeminal neuralgia; chronic lower back pain; and central post-stroke pain. 10. The method of claim 1, wherein the subject is a human. 11. The method of claim 1, wherein the pain is neuropathic pain and said neuropathic pain has the following etiologies: alcohol abuse; diabetes; eosinophilia-myalgia syndrome; Guillain-Barre syndrome; exposure to arsenic, lead, mercury, and thallium; HIV/AIDS; malignant tumors; amiodarone, aurothioglucose, cisplatinum, dapsone, stavudine, zalcitabine, didanosine, disulfiram, FK506, hydralazine, isoniazid, metronidazole, nitrofurantoin, paclitaxel, phenyloin and vincristine; monoclonal gammopathies; multiple sclerosis; post-stroke central pain, postherpetic neuralgia; carpal tunnel syndrome, cervical or lumbar radiculopathy, complex regional pain syndrome, spinal cord injury and stump pain; trigeminal neuralgia; vasculitis; vitamin B6 megadosing; and vitamin B12, B1, B6, or E deficiencies. 12. The method of claim 1, wherein the composition further comprises a component selected from the group consisting of: phenytoin; carbamazepine; barbiturates; Phenobarbital; pentobarbital: mephobarbital: trimethadione: mephenytoin; paramethadione; phenthenylate; phenacemide; metharbital; benzchlorpropanmide; phensuximide; primidone; methsuximide; ethotoin; aminoglutehimide; diazepam; clonazepam; clorazepate; fosphenytoin; ethosuximide; valporate; felbamate; gabapentin; lamotrigine; topiramate; vigrabatrin; tiagabine; zonisamide; clobazam; thiopental; midazoplam; propofol; levetiracetam; oxcarbazepine; CCPene; GYK152466; sumatriptan; non-steroidal anti-inflammatory drugs; neuroleptics; corticosteroids; vasoconstrictors; beta-blockers; antidepressants; anticonvulsants; Depakote; Ergot alkaloids; tryptans; Acetaminophen; caffeine; Ibuprofen; Proproxyphene; oxycodone; codeine; isometheptene; serotonin receptor agonists; ergotamine; dihydroergotamine; sumatriptan; propranolol; metoprolol; atenolol; timolol; nadolol; nifeddipine; nimodipine; verapamil; aspirin; ketoprofen; tofenamic acid; mefenamic acid; naproxen; methysergide; paracetamol; clonidine; lisuride; iprazochrome; butalbital; benzodiazepines; divalproex sodium, a blood brain barrier permeability enhancer and a hyperosmotic agent. 13. The method of claim 12, wherein said administering comprises simultaneous or sequential administration of one or more agents in the same formulation or unit dosage form or in separate formulations or unit dosage forms.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.